Baricitinib in Combination with Remdesivir is Used to Treat COVID-19 Positive Patients, Natco Pharma Says
Drug maker Natco Pharma has received emergency use authorization for baricitinib tablets, 1 mg, 2 mg and 4 mg, from the Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib, in combination with remdesivir, is used for the treatment of COVID-19 positive patients, according to a Natco release on approval.
The company said it intends to apply for a compulsory license based on emergency use and in light of the severe and severe public health emergency across India due to the pandemic. It is set to launch the product this week, to make it available to patients across India, the statement said.